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INTRODUCTION 
Diabetes mellitus is a common endocrine disease which is global public health 
problem. Cardio vascular diseases are most common causes of disability and 
premature mortality in patients with diabetes  .80% of the diabetic patients 
were died due to thrombo embolic  CVD. In patients with diabetes mellitus, 
persistent hyperglycemia exposes red blood cells to elevated glucose 
concentration ,thus resulting in glycation of hemoglobin prothrombin 
,fibrinogen and other proteins involved in clotting mechanisms .  The glycation 
results in incomplete activation and function of the clotting cascade.  Glycation 
of intrinsic and extrinsic clotting proteins will decrease the availability of these 
proteins which affect the clotting capacity. 
      Hypercoagulability in diabetic patients may induce atherosclerosis and act 
as risk factor for cardio vascular diseases. Now a days  all modern  coagulation 
test are available inspite of  PT and APTT  are still basic investigation in all 
clinical laboratories.  
      PT and APTT the marker for activation of extrinsic and intrinsic  pathway 
respectively.  The hypercoaguability state demonstrated by shortened PT and 
APTT in diabetes mellitus may cause occlusive thrombus within a coronary 
artery.  Therefore shortened PT and APTT  value is the risk factors for 
thromboembolic  cardiovascular disease in type 2 diabetic patients. 
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     Therefore, this study aimed to investigate the importance of routine 
determination PT and APTT  in order to assess the coagulation impairment in 
diabetes mellitus to prevent the thromboembolic cardiovascular diseases 
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AIM OF THE STUDY 
1. To assess the prevalence of coagulation impairment in type2 diabetes 
mellitus patients. 
2. To assess the relationship between coagulation impairment and long 
term glycemic control with reference to HbA1c. 
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MATERIALS AND METHODS 
SOURCE OF STUDY: 
Data consists of primary data collected by the principal investigator directly 
from the cases of TYPE 2 DIABETES MELLITUS attending outpatient 
department in Coimbatore medical college Hospital. 
DESIGN OF STUDY: CROSS SECTIONAL STUDY 
PERIOD OF STUDY: ONE YEAR 
METHODOLOGY:  
This is a cross sectional study among 200 Type2 diabetes mellitus patients 
attending outpatient department in Coimbatore Medical College Hospital in the 
medical ward of Coimbatore Medical College Hospital. All the tests are done 
with due permission from the institutional Ethical Committee and informed 
consent is obtained from the subjects. 
INCLUSION CRITERIA: 
All Type 2 Diabetes mellitus patients above 40 years  with HbA1c>8 
EXCLUSION  CRITERIA: 
1: Patients on drugs altering coagulation profile. 
2: Patients with liver disease. 
3: Patients with history of coagulation disorders. 
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4: Patients with malignancy, coronary artery disease, cerebro vascular accident. 
5: Patients with clinical evidence of macro vascular and micro vascular 
complications of diabetes mellitus. 
6:Consent not given.    
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REVIEW OF LITERATURE. 
 HISTORICAL ASPECTS: 
Since 3500 years many polyuric diseases have been known to medical science. 
The word, “Diabetes” derives from  the  greek word siphon. The term, 
“Mellitus.” meaning  honey was added by ROLLO in the late 18 th century. 
Chevreul identified the sugar in the diabetic urine to be glucose in 1815. 
Adding tribute to Indian medicine is the fact that the two Hindu physicians 
Charak and Sushrut,(400 and 500 bc)  recognized the sweetness of diabetic 
urine by noting the assembly of ants around the urine sample. Later some 
important discoveries turned  the disease DIABETES more popular. Few 
among them include pancreatectomy causing severe diabetes discovered by 
Minkowski and  Von mering in 1889,discovery of insulin by Banting in 1921 
and its use in treatment around 1922. Later, the subdivision of Diabetes 
mellitus into type 1( insulin dependent) and type 2(non insulin dependent) on 
the basis of etiology was done.(1). The recent discoveries in the 20 th century 
have taken both the understanding and treatment to remarkable heights in 
achieving  glycemic control and prevention of complications. 
 
EPIDEMIOLOGY AND  PREVALENCE:  
In 2015, the International Diabetes Federation  had estimated that globally 415 
million people  had diabetes and  75% of the live in low- and middle-income 
countries. In the age group 20–79 years, about 8.8% had diabetes globally and 
an  estimated 46.5% of them remain undiagnosed. The Western Pacific region 
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had the highest number of  diabetes patients  with 153.2 million, and  North 
America had the highest prevalence rate with 12.9% and the Caribbean. The 
second most populous country in the world is India and has an estimated 69.2 
million affected in 2015. This figure is projected to rise to 123.5 million by 
2040.  The  diabetic  population  is expected to reach 642 million by 2040, an 
increase of 55% .The countries with rapidly growing economies, such as India 
and China would be facing the largest increases.(1) Over the past two decades 
the global prevalence of diabetes has soared up from 30 million to 382 million 
cases from 1985 to 2013. In 2013, the number of diabetic patients in India was 
around 65 million cases. Projection studies done by International Diabetes 
Federation Projects show that by the year 2035 there would be around 592 
million diabetics. Interestingly, the phenotypic characteristics of Diabetes 
appears to be different from  that in USA and Europe in that there is younger 
age of onset , lower Body Mass Index( BMI), increased truncal adiposity and 
reduced insulin secretory capacity.(2). Globally, an estimated 422 million 
adults are living with diabetes mellitus, according to the latest 2016 data from 
the World Health Organization (WHO).(3)  
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Diabetes is becoming  a potential epidemic in India with more than 62 million 
diabetic individuals currently diagnosed with the disease. In 2000, India (31.7 
million) had  the highest number of people with diabetes mellitus followed by 
China (20.8 million) with the United States (17.7 million) in second and third 
place respectively(15). 
Increasing incidence rates  and demographic shifts (i.e., the aging of the 
population) and  rise of overweight and obesity as well as increasingly 
sedentary lifestyles are responsible for the increasing trends.  Globally same 
trend is seen, with projections of 550 million (approximately half undiagnosed) 
to be affected by 2030. Type 2 diabetes is being increasingly recognized in 
obese adolescents and young adults but  older age remains a major risk factor 
for type 2 diabetes(6). The incidence of diabetes is rising. Globally, in 2015, 
415 million people had diabetes  (10% of the world adult population), and it 
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might reach 642 million by 2040. This global pandemic principally involves 
type 2 diabetes;  
 Differences in genetic factors, as well as environmental factors like greater 
longevity, obesity, unsatisfactory diet, sedentary lifestyle, increasing  
urbanisation and economic development are linked with variable prevalence. 
Migrant populations to industrialized countries, as in Asian and Afro-
Caribbean immigrants to the UK or USA demonstrated increased prevalence. 
Children and adolescents also develop type 2 diabetes, seen particularly in 
some ethnic groups such as Hispanics, non-Hispanic blacks and Asian 
Indians.(7)  Diabetes is becoming a  growing menace to global health. 
Worldwide, diabetes probably affects 250 million people. Eightfold less in 
1985 (30 million) the world prevalence is predicted to reach 380 million by 
2025.(8) 
CLASSIFICATION AND DIAGNOSIS OF DIABETES: 
Based on the pathogenic process that leads to hyperglycemia,  two broad 
categories of DM, designated type 1 and type 2 . However, other forms of 
diabetes are also recognized  in which the pathogenesis is better understood.(2) 
Abnormal glucose homeostasis precedes both type 1 and type 2 diabetes as the 
pathogenic processes progress. Complete or near-total insulin deficiency 
characterizes type 1 DM while variable degrees of insulin resistance, impaired 
insulin secretion, and increased glucose production characterizes Type 2 DM 
which is heterogeneous in nature. A period of abnormal glucose homeostasis 
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precedes Type 2 DM,classified as impaired fasting glucose (IFG) or impaired 
glucose tolerance (IGT).(2) (TABL E 417-1  
Etiologic Classification of Diabetes Mellitus(2) 
1. Type 1 diabetes (beta cell destruction, usually leading to absolute insulin 
deficiency) 
A. Immune-mediated 
B. Idiopathic 
II. Type 2 diabetes (may range from predominantly insulin resistance with 
relative insulin deficiency to a predominantly insulin secretory defect with 
insulin resistance)   
III. Other specific types of diabetes 
A. Genetic defects of beta cell development or function characterized by 
mutations in: 
1. Hepatocyte nuclear transcription factor (HNF) 4α (MODY 1) 
2. Glucokinase (MODY 2) 
3. HNF-1α (MODY 3) 
4. Insulin promoter factor-1 (IPF-1; MODY 4) 
5. HNF-1β (MODY 5) 
6. NeuroD1 (MODY 6) 
7. Mitochondrial DNA 
8. Subunits of ATP-sensitive potassium channel 
9. Proinsulin or insulin 
10. Other pancreatic islet regulators/proteins such as KLF11, PAX4, BLK, 
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GATA4, GATA6, SLC2A2 (GLUT2), RFX6, GLIS3 
B.  Genetic defects in insulin action 
1. Type A insulin resistance 
2. Leprechaunism 
3. Rabson-Mendenhall syndrome 
4. Lipodystrophy syndromes 
C.  Diseases of the exocrine pancreas—pancreatitis, pancreatectomy, 
neoplasia, cystic fibrosis, hemochromatosis, fibrocalculous 
pancreatopathy, mutations in carboxyl ester lipase  
D.  Endocrinopathies—acromegaly, Cushing’s syndrome, glucagonoma, 
pheochromocytoma, hyperthyroidism, somatostatinoma, aldosteronoma 
E.  Drug- or chemical-induced—glucocorticoids, vacor (a rodenticide), 
pentamidine, nicotinic acid, diazoxide, β-adrenergic agonists, thiazides, 
calcineurin and mTOR inhibitors, hydantoins, asparaginase, α-
interferon, protease inhibitors, antipsychotics (atypicals and others), 
epinephrine 
F.  Infections—congenital rubella, cytomegalovirus, coxsackievirus 
G.  Uncommon forms of immune-mediated diabetes—”stiff-person” 
syndrome, anti-insulin receptor antibodies 
H.  Other genetic syndromes sometimes associated with diabetes— 
Wolfram’s syndrome, Down’s syndrome, Klinefelter’s syndrome, 
Turner’s syndrome, Friedreich’s ataxia, Huntington’s chorea, Laurence-
13 
 
Moon- Biedl syndrome, myotonic dystrophy, porphyria, Prader-Willi 
syndrome 
IV.  Gestational diabetes mellitus (GDM) 
Abbreviation: MODY, maturity-onset diabetes of the young. 
CRITERIA FOR THE DIAGNOSIS OF DIABETES MELLITUS(2): 
•  Diabetes symptoms along with random blood glucose concentration 
≥11.1 mmol/L (200 mg/dL) or 
•  Fasting plasma glucose ≥7.0 mmol/L (126 mg/dL) or 
•  Hemoglobin A1c ≥ 6.5%c or  
•  2-h plasma glucose ≥11.1 mmol/L (200 mg/dL) during an oral glucose 
tolerance test. 
Random is defined as without regard to time since the last meal.  
Fasting is defined as no caloric intake for at least 8 h.  
Hemoglobin A1c test should be performed in a laboratory using a method 
approved by the National Glyco hemoglobin Standardization Program and 
correlated to the reference assay of the Diabetes Control and Complications 
Trial. 
The test should be performed using a glucose load containing the equivalent of 
75 g anhydrous glucose dissolved in water, not recommended for routine 
clinical use. 
Note: In the absence of unequivocal hyperglycemia and acute metabolic 
decompensation, 
These criteria should be confirmed by repeat testing on a different day. 
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Source: Adapted from American Diabetes Association: Diabetes Care 37(Suppl 
1):S14, 
 
Abnormal glucose homeostasis (2) 
(1)  FPG = 5.6–6.9 mmol/L (100–125 mg/dL)- impaired fasting glucose 
(IFG); 
(2)  Following an oral glucose challenge, plasma glucose levels between 7.8 
and 11 mmol/L (140 and 199 mg/dL) - impaired glucose tolerance 
(IGT) 
(3)  HbA1c of 5.7–6.4%.  
An HbA1c of 5.7–6.4%, IFG, and IGT in all three groups points towards 
a greater risk of progressing to type 2 DM and an increased risk of 
cardiovascular disease. They must  be counselled about ways to decrease these 
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risks. Other  terms  used are prediabetes, increased risk of diabetes, or 
intermediate hyperglycemia (World Health Organization) .The above 
mentioned values for  fasting plasma glucose, the glucose following an oral 
glucose challenge, and HbA1c are continuous variables. They do not indicate  
discrete categories. The  most reliable current criteria for the diagnosis of DM  
are  HbA1c or the FPG. They are also  convenient tests for identifying DM in 
asymptomatic individuals. Oral Glucose Tolerance Test, is not often used in 
routine clinical care, although they are still valid to diagnose DM. 
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SCREENING: (7) 
FPG or the HbA1c are widely used as a screening test for type 2 DM  because  
(1)  large number of individuals  are asymptomatic and unaware that they 
have the disorder,   
(2)  Before diagnosis type 2 DM may be present for up to a decade,as 
suggested by epidemiological studies.  
(3)  Presence of one or more complications of  type 2 DM at the time of their 
diagnosis,  
(4)  Diagnosis of prediabetes leads to measures involving diabetes 
prevention.  
The ADA recommends screening all individuals 
1.   >45 years every 3 years and screening individuals at an earlier age if t
 hey are overweight (BMI > 2.25 kg/m2 or ethnically relevant 
definition for overweight) and have one additional risk factor for 
diabetes. 
  Long asymptomatic period of hyperglycemia is rare in Type 1 DM prior 
to the diagnosis,contrary to Type 2 DM.  Although many immunologic markers 
are available  for type 1 DM  available, clinical interventions beneficial to 
identify high risk individuals who would develop Type 1 DM are not available. 
So their routine use outside a clinical trial is discouraged, 
  In contrast individuals at risk of developing Type 2 DM must be 
considered for screening as they may have asymptomatic hyperglycemia for 
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many years preceding diagnosis. If screening is not done up to 30% might go 
undiagnosed. 
  Identification of people with prediabetes is also possible by screening. 
  Depending on the clinical setting and the preference of the patient, 
screening can be conducted with HbA1c,fasting blood glucose or oral glucose 
tolerance test.   
For asymptomatic children with BMI above the 85th percentile for age and sex 
along with any two of the following risk factors: 
1.  Family history of type 2 diabetes,  
2. High-risk race/ethnicity. 
3.  Evidence of insulin resistance or features associated with insulin 
resistance (acanthosis nigricans, hypertension, dyslipidemia, polycystic ovary 
syndrome, or small-forgestational- age birth weight).  
Pregnant women with risk factors for diabetes should be screened for 
undiagnosed diabetes at the first prenatal visit. Otherwise, a 75-g oral glucose 
tolerance test should be performed at 24 to 28 weeks of gestation to detect 
gestational diabetes.(6) 
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AETIOPATHOGENESIS:(2,6) 
RISK FACTORS: 
 
Pathology(1,5,7) 
 The diagnosis of Type 2 diabetes is a process of exclusion after type 1 diabetes 
and other types are  ruled out. Type 2 DM  is a highly heterogeneous disease.  
In the natural history of typical type 2 diabetes initially there is insulin 
resistance. This  leads to elevated insulin secretion to maintain normal blood 
glucose levels. But in susceptible individuals in the face of  increased demand 
for insulin the pancreatic β cells are unable to sustain the and a slowly 
progressive insulin deficiency develops. Some patients having background risk 
factors like obesity and ethnicity  develop diabetes at a young age with insulin 
resistance. 
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Older patients, may have more pronounced β-cell failure inspite of being non-
obese  and may develop diabetes. “Relative insulin deficiency” is the hall mark 
of Type 2 DM. There is insufficient insulin production to overcome the 
resistance to insulin action. In contrast patients with type 1 diabetes have rapid 
loss of insulin production, leading to  ketoacidosis and death if the insulin 
replacement is not done.  
Insulin resistance and the metabolic syndrome:(7,8) 
Type 2 diabetes and its pre-diabetes antecedents along with hypertension, 
dyslipidaemia (characterized by elevated levels of small dense low-density 
lipoprotein (LDL) cholesterol and triglycerides, and a low level of high-density 
lipoprotein (HDL) cholesterol), non-alcoholic fatty liver disease  and, in 
women, polycystic ovarian syndrome together consititute a constellation of 
disorders termed as ‘insulin resistance syndrome’ or ‘metabolic syndrome. This 
syndrome is more common in obese individuals.   
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Multiple defects in insulin signaling is likely to contribute to insulin resistance 
thus affecting several tissues. The adipocyte theory is convincing as obesity is a 
major cause of increased insulin resistance. Large quantities of FFAs released 
by the metabolically active central and intra abdominal adipose tissue  may 
induce insulin resistance as they compete with glucose as a fuel supply for 
oxidation in peripheral tissues such as muscle. (2,6) 
Adipose tissue also releases a number of hormones including a variety of 
peptides, called ‘adipokines’ ( structurally similar to immunological 
‘cytokines’).They act on specific receptors to influence sensitivity to insulin in 
other tissues. Because the venous drainage of visceral adipose tissue is into the 
portal vein, central obesity may have a particularly potent influence on insulin 
sensitivity in the liver, and thereby adversely affect gluconeogenesis and 
hepatic lipid metabolism.(2)  
Physical inactivity down regulates insulin sensitive kinases and permits 
accumulation of Free fatty acids within the skeletal muscle. Sedentary and 
obese  people are therefore more insulin-resistant than active people with the 
same degree of obesity. Physical activity augments non-insulin-dependent 
glucose uptake into muscle thus reducing the ‘demand’ on the pancreatic β 
cells to produce insulin. Non-alcoholic fatty liver disease-NAFLD 
characterized by fatty infiltration of liver is commonly associated with central 
obesity as well as type 2 DM. Effective treatment of the diabetes improves this 
condition  but, despite this, some patients progress to non-alcoholic 
steatohepatitis (NASH)and cirrhosis.(2,7) 
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Pancreatic β-cell failure: (2) 
Early stages of type 2 diabetes is characterized by modest reduction in the total 
mass of pancreatic islet tissue . Around 50% of β-cell function has been lost at 
the time of diagnosis. Subsequently there is a progressive decline in β-cell 
function. One typical and most consistent  pathological finding of type 2 
diabetes, is deposition of amyloid in the islets. The Toxic effects of  elevated 
plasma glucose and FFAs on pancreatic β cells also impairs insulin secretion.  
The β-cell mass is unchanged inspite of reduced β-cell numbers and glucagon 
secretion is increased,contributing  to hyperglycaemia. 
Genetic predisposition(2,6) 
Susceptibility studies in different ethnic groups and  studies in monozygotic 
twins with  100% concordance rates highlights the importance of genetic 
factors in type 2 DM. However, both genetic and environmental factors jointly 
influence the development of diabetes. 
Genome-wide association studies have identified over 70 genes or gene regions 
concerned with  β-cell function or in regulation of cell cycling and turn over 
that are associated with type 2 diabetes, each exerting a small effect. Altered 
regulation of β-cell mass is a key factor. Many genes demonstrate 
polymorphisms and are associated with insulin secretion. Variation in TCF7L2 
is supposed to be the largest population genetic effect described till date.  When 
two copies of the risk variant for this gene are inherited, there is  twofold 
increase in risk of developing type 2 diabetes. In general, other common 
variants explain much lower risk than this, many explaining less than a 10% 
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increase in risk only; as only about 10% of the genetic variance in type 2 
diabetes is explained by these common genetic variants, this has led some to 
question the relevance of finding diabetes genes. However, it should be noted 
that, within a population, the distribution of risk variants will vary, with some 
patients having inherited a high genetic burden (e.g. more than 40 risk variants) 
and others having inherited very few. When studies compare those in the top 
20% of this risk band with the lowest 20%, those at highest risk are over 2.5 
times more likely to develop diabetes. 
Some rare genetic variants affect only a small proportion of the population, but 
have large clinical effects. For example, in a Greenlandic population, 3% of 
people carry a homozygous variant in an insulin signalling gene, TBC1D4, that 
results in muscle insulin resistance; these individuals are over 10 times more 
likely to develop type 2 diabetes. 
Environmental and other risk factors: (7,8) 
Diet and obesity: 
Epidemiological studies had  shown that overeating is strongly associated with 
Type 2 DM, especially when combined with under-activity and obesity. 
Middle-aged people with diabetes  are fatter and less active as they eat 
significantly more than their non-diabetic siblings. A body mass index (BMI) 
of more than 30 kg/m2 confers a 10 fold increased risk of developing type 2 
Diabetes . Majority of individuals with type 2 diabetes are obese.But only a 
small number of obese people develop diabetes because most  obese people are 
able to compensate for the increased demand resulting from obesity and insulin 
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resistance by increasing their insulin secretion. But some obese people have  
reduced β-cell mass,  genetically impaired β-cell function, or a susceptibility of 
β cells to attack by toxic substances such as FFAs or inflammatory 
cytokines.(17 -21) 
Age : 
Middle-aged and older individuals  commonly develop Type 2 diabetes. In the 
UK, it affects 10% of the population over 65, and more than 70% of all cases of 
diabetes occur after the age of 50 years. 
 
Ethnicity: (7) 
Ethnicity and race are  a major risk factor for development of diabetes. For 
example, within the Americas , the diabetes prevalence is lowest in Alaskan 
Natives at 5.5%, non-Hispanic whites score a moderate 7.1%,  non-Hispanic 
blacks show a high 13% and highest in Native Americans at 33%. This 
considerable variation in prevalence is due to a  number of different factors, 
such as  higher BMI and lower socioeconomic class in high-risk groups in the 
USA; differences in genetic risk. And differences in health behaviour, e.g. 
decreased physical activity and increased smoking. Studies in high-risk ethnic 
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groups largely demonstrate more central/visceral adiposity  and increased  
insulin resistance  than in the lower-risk groups. 
PREVENTION :(6) 
 Not only the considerable global burden but also the  presence of  period of 
heightened risk i.e. pre-diabetes  (i.e., impaired glucose tolerance and impaired 
fasting glucose) which allows to identify patients likely to benefit-both these 
have made it an appropriate target for prevention .  
Lifestyle change (i.e., weight loss and exercise) and several antidiabetic 
medications have been the most widely studied interventions. 
Lifestyle Change : (7) 
The Diabetes Prevention Program, conducted in the United States  in the 
beginning of 1990s was the largest and longest diabetes prevention study to 
date. Individuals at high risk for type 2 diabetes on the basis of the pre-diabetic 
hyperglycemia (fasting glucose concentration of 95 to 125 mg/dL and 2-hour 
glucose concentration of 140 to 199 mg/dL) and  presence of overweight or 
obesity were randomly assigned to an intensive lifestyle program or a 
medication intervention (metformin vs. placebo) and observed for a mean of 3 
years. The lifestyle intervention allotted was a  modest weight reduction 
(minimum 7% of body weight) with a reduced fat, hypocalorie diet and 
moderate-intensity physical activity for 150 minutes/week.  
Incident diabetes (determined by oral glucose tolerance test) was reduced by 
58% compared with placebo, although the risk reduction was somewhat 
diminished (34%) with longer term follow-up of the cohort.The major predictor 
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of diabetes prevention was successful weight loss with every  kilogram of 
weight loss reducing diabetes risk by 16%. The Finnish Diabetes Prevention 
Study also reported similar findings. Even among individuals who did not lose 
weight, achieving the physical activity goal was associated with lower diabetes 
risk. 
Medication : (2,7) 
Metformin is found to reduce  the risk of diabetes by 31% in the Diabetes 
Prevention Program. In smaller studies, the α-glucosidase inhibitor acarbose 
demonstrated modest reduction in diabetes risk (~25%). The thiazolidinediones 
(e.g., troglitazone and rosiglitazone) have also shown diabetes prevention 
effects but are not widely used for this purpose because of concerns about their 
long-term safety. None of these drugs is approved by the Food and Drug 
Administration for diabetes prevention. 
Recommendations: (2)  
For individuals at high risk of diabetes, the recommended interventions are 
both Lifestyle modification and metformin. Those with overweight or obesity 
plus an additional risk factor, such as family history of diabetes, those with 
defined glucose abnormalities (impaired glucose tolerance, impaired fasting 
glucose) are candidates for these recommendations. online resources for these 
recommendations are available at (http://www.bsc.gwu.edu/dpp/lifestyle/ 
dpp_part.html). Both lifestyle modification and metformin have  demonstrated 
positive effects on cardiovascular risk factors, but whether  microvascular or 
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macrovascular complications could be prevented or not remains to be 
determined. 
NORMAL PHYSIOLOGY: (2) 
ISLET FUNCTION AND INSULIN SECRETION: (2) 
Numerous small endocrine organs known as islets of Langerhans, which are 
located in the pancreas regulate the fuel homeostasis. The only source of the 
polypeptide hormone insulin are located in the islets called β cells. Islet β cells 
are equipped to detect changes in circulating nutrients.  Insulin secretory 
response is initiated by elevated levels of nutrients from β cells.  Insulin  
enables  storage of circulating nutrients in liver, muscle, and adipose tissue. 
Hormones, neurotransmitters, and neuropeptides, can modify the insulin 
secretory response to circulating nutrients.  Integration between metabolic fuel 
intake, usage, and storage is made possible by Complex interactions between 
islet cells, the autonomic nervous system, and gastrointestinal incretin 
hormones. 
MECHANISM OF INSULIN ACTION: (2) 
The insulin receptor is a transmembrane protein. The α subunits are located 
extracellularly and form ligand binding sites. The β subunits form a 
transmembrane-spanning segment that separates the extracellular regions from 
the intracellular tyrosine kinase. Insulin-like peptides  are a superfamily of  
structurally related peptides encoded by human genome—including insulin, 
insulin-like growth factor-1 (IGF1) and insulin-like growth factor-2 (IGF2). 
They activate five receptor tyrosine kinases assembled from two genes.  Insulin 
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resistance is an important risk factor for the metabolic syndrome—
hyperglycemia, hyperinsulinemia, dyslipidemia and hypertension—and its 
progression to cardiovascular disease, non-alcoholic fatty liver disease, and 
type 2 diabetes. 
Insulin receptor substrates (IRS) proteins - tandem structurally similar 
pleckstrin homology (PH) and phosphotyrosine-binding (PTB) domains 
followed by a long, unstructured tail of tyrosine and serine phosphorylation 
sites that coordinate insulin and insulin-like growth 
factor signaling.  
Insulin and IGF1 stimulationphosphorylation of tyrosine residues in the IRS 
tail  binding to the SH2 domains of various signaling proteins ( 85 kDa 
regulatory subunit (p85) of the phosphatidylinositol 3-kinase (PI3K) and the 
RAS GTP exchange factor 
Grb2∙Sos) 
IRS1 expression  regulated by transcriptional repressors, including AP2β 
(transcription factor AP-2-beta), or the p160 family of nuclear receptor 
coactivators p/CIP (p300/CBP/cointegrator-associated protein) and SRC1 
(steroid receptor coactivator-1). 
IRS2 transcription  regulated by multiple factors, including CREB (cAMP 
response element binding protein) and its coactivator CRTC2 (CREB-regulated 
transcription coactivator 2), FOXO1/3, NFAT (nuclear factor of activated T 
cells), TFE3 (transcription factor E3), HIF2α 
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(hypoxia-inducible factor-2α encoded by Epas1), and SREBP1 (sterol 
regulatory element binding protein 1).(21-25) 
IRS1 and IRS2  poly ubiquitinylated during chronic inflammatory states, 
nutrient excess, and hyperinsulinemia through various tissue specific 
mechanisms. Degradation of IRS1 or IRS2 promoted  by several pathways:  
(1) proinflammatory cytokine-mediated upregulation of SOCS1/3 (suppressors 
of cytokine signaling);  
(2) the cullin-RING E3 ubiquitin ligase 7 (CRL7);  
(3) CBLB (Cbl proto-oncogene B), a RING-type E3 ubiquitin ligase. 
(4) MG53 (mitsugumin 53), a TRIM (tripartite motif-containing) family E3 
ubiquitin ligase. 
IRS1 and IRS2  regulated through a complex mechanism  phosphorylation 
of more than 50 serine/threonine residues (phospho-S/Ts) located in the long 
tail regions. 
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 INSULIN ACTION ON TARGET CELL. 
Pancreatic β cells unique source of insulin secretion. They are dependent on  
insulin and insulin-like growth factor signaling for growth, function and 
survival. Insulin and insulin-like growth factor signaling is  regulated through 
multifactor transcriptional control of IRS2 through the action of FOXO1/3, 
NFAT, and the CREB∙CRTC2. 
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REGULATION OF GLUCOSE HOMEOSTASIS: (2,7) 
 
INSULIN BIOSYNTHESIS AND SECRETION: (2,7) 
Insulin  produced in the beta cells of the pancreatic 
isletssynthesized as a single-chain 86-amino-acid precursor polypeptide, 
preproinsulin proteolytic processing proinsulin. Proinsulin is isomeric to 
insulin-like growth factors I and II, which bind weakly to the insulin receptor. 
Cleavage of an internal 31-residue fragment from proinsulin  C peptide and 
the A (21 amino acids) and B (30 amino acids) chains of insulin connected 
by disulfide bonds. The mature insulin molecule and C peptide are stored 
together and co-secreted from secretory granules in the beta cells.  C 
peptideuseful marker of insulin secretion and allows discrimination of 
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endogenous and exogenous sources of insulin in the evaluation of 
hypoglycemia ,as C peptide is cleared more slowly than insulin. 
  Pancreatic beta cells co-secrete islet amyloid polypeptide (IAPP) or 
amylin, a 37-amino-acid peptide, along with insulin.  IAPPit is the major 
component of the amyloid fibrils found in the islets of patients with type 2 
diabetes.Human insulin is manufactured  by recombinant DNA technology; 
structural alterations at one or more amino acid residues modify its physical 
and pharmacologic characteristics,thus explaining the availability of various 
forms of insulin. 
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INSULIN ACTION: (7) 
After secretion into the portal venous system, ~50% of insulin is  removed and 
degraded by the liver. Unextracted insulin enters the systemic circulation 
binding to target receptorsStimulation of  intrinsic tyrosine kinase 
activity receptor autophosphorylation the recruitment of intracellular 
signaling molecules(insulin receptor substrates (IRS))complex cascade of 
phosphorylation and dephosphorylation reactionswidespread metabolic and 
mitogenic effects of insulin. Activation of the phosphatidylinositol-3′-kinase 
(PI-3-kinase) pathway  translocation of a facilitative glucose transporter 
(e.g., GLUT4) to 
the cell surface glucose uptake by skeletal muscle and fat. 
 
INSULIN SYNTHESIS AND SECRETION. 
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 Assessment of Long-Term Glycemic Control (2,6) 
 Measurement of glycated hemoglobin (HbA1c)  standard method for 
assessing long-term glycemic control Consistent elevation of plasma 
glucoseincrease in non enzymatic glycation of hemoglobin reflects the 
glycemic history over the previous 2–3 months ( RBC’S have an average life 
span of 120 days (glycemic level in the preceding month contributes about 50% 
to the HbA1c value). Measurement of HbA1c at the “point of care” more 
rapid feedback   and adjustment of therapy. HbA1c should be measured in all 
individuals with DM during their initial evaluation and as part of their 
comprehensive diabetes care. HbA1c primary predictor of long-term 
complications of DM. HbA1c and SMBG  complementary to each 
other.Recent intercurrent illnesses impacts the SMBG measurements but not  
the HbA1c. Likewise, postprandial and nocturnal hyperglycemia may not be 
detected by the SMBG of fasting and preprandial capillary plasma glucose but 
will be reflected in the HbA1c. In standardized assays, the HbA1c 
approximates the following mean plasma glucose values: an HbA1c of 6% = 
7.0 mmol/L (126 mg/dL), 7% = 8.6 mmol/L (154 mg/dL), 8% = 10.2 mmol/L 
(183 mg/dL), 9% = 11.8 mmol/L(212 mg/dL), 10% = 13.4 mmol/L (240 
mg/dL), 11% = 14.9 mmol/L (269 mg/dL), and 12% = 16.5 mmol/L (298 
mg/dL).  
In patients achieving their glycemic goal, the ADA recommendation- 
measurement of the HbA1c at least twice per year. More frequent testing 
(every 3 months) is warranted when glycemic control is inadequate or when 
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therapy has changed. Laboratory standards for the HbA1c test have been 
established and should be correlated to the reference assay of the Diabetes 
Control and Complications Trial (DCCT). HbA1c result is affected by Clinical 
conditions such hemoglobinopathies, anemias, reticulocytosis, transfusions, 
and uremia . when the HbA1c is inaccuratefructosamine assay (measuring 
glycated albumin) reflects the glycemic status over the prior 2 weeks. 
Advanced Glycation End Products: (6) 
Advanced glycation end products (AGEs)  heterogeneous group of 
compoundsformed  by the nonenzymatic interaction of glucose with amino 
groups on proteins. Glycation occurs continuously in vivo  and markedly 
accelerated in the presence of hyperglycemia. Indeed, the HbA1c test to 
monitor the chronic level of glycemia was the result of observations of the 
glycosylation of subfractions of adult hemoglobin. Levels of AGEs in serum 
and tissues (e.g., skin collagen) correlate with diabetic vascular complications 
and mean glucose levels over time. AGEs alter the properties and function of 
long-lived proteins(collagen and elastin) vascular stiffness and increases in 
basement membrane thickness. AGE binding to 
specific cell surface receptors (e.g., receptors for AGE, RAGE) on 
macrophages and endothelial cellsactivation of signaling cascades  
inflammation and oxidative stress.  AGERAGE interaction activation of  the 
transcription factor NF-κBmultiple pathologic changes in gene expression.  
AGE formation is a key process mediating hyperglycemic damage.  
Activation of Protein Kinase C : (6) 
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Intracellular hyperglycemia  increased de novo synthesis of diacylglycerol 
activator of the protein kinase C family of enzymes. Activation of protein 
kinase C  complex network of intracellular signaling that alters gene 
expression enhanced angiogenesis, vasoconstriction, vascular permeability 
(by increases in vascular endothelial growth factor), cytokine activation, and 
extracellular matrix expansion.-->development of microvascular complications 
(especially retinopathy) and atherosclerosis.  
 
Glycalation of haemoglobin, prothrombin, fibrinogen and other proteins 
involved in clotting mechanisms  incomplete activation and function of the 
clotting cascade . Glycation of intrinsic and extrinsic clotting proteins 
decreased  availability of these proteins which affect the clotting capacity.(9) 
Premature atherosclerosis and more extensive vascular disease--. plaque 
rupture and thrombus formation(4). In addition, these individuals have  platelet 
hyper- 
reactivityincreased thrombotic tendency and increased activation of pro-
thrombotic coagulation factors coupled with decreased fibrinolysis.(5)  
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Thrombosis and vascular occlusion: (7,9,11)  
Complicated plaques with thinner caps and inflammatory infiltrates more 
prone to rupture, irrespective of size. 
Plaque rupture  series of events  formation of a thrombus over a ruptured ⁄ 
fissured plaque acute complications of CVD [unstable angina and 
myocardial infarction (MI), stroke. Adherence of platelets to the rupturing 
plaque  local activation of coagulation, the formation of a crosslinked fibrin 
clot and the development of an occlusive platelet rich fibrin mesh. Fibrin  
consistent component of human atherosclerotic plaques. Fibrin plays a role in 
the development of vascular lesions at an early stage . other events include: 
1.Endothelial dysfunction with decreased nitric oxide (NO) production and 
decreased flow-mediated dilatation. 
2.Formation of macrophage-derived lipidrich foam cells leading to fatty streak 
formation. 
3.Generation of a vulnerable plaque prone to rupture with associated occlusive 
thrombus formation. 
 Concurrent with these changes, profound changes in coagulation like 
inhibition of the fibrinolytic pathway, increased levels of hepatic-derived 
coagulation proteins, and loss of regulation of platelet activation also take 
place. More diffuse vascular lesions often affecting distal aspects of coronary 
arteries are seen in Diabetes Discrete coronary lesions are relatively more lipid 
rich with increased macrophage infiltration and intra-plaque thrombosis 
compared with nondiabetic subjects. in large part explains The high risk of 
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CVD in diabetes and related conditions is explained by the close association 
between the risk clustering observed in diabetes and the pathological changes 
observed in coronary arteries.(21 -30) 
Diabetes mellitus and endothelial dysfunction: (11,12) 
The vascular endothelium  serves the following important functions: 
1.provides a physical barrier between the vessel wall and its luminal contents 
2. secretes mediators that regulate vascular tone 
3.interacts with circulating proteins and cells to regulate platelet adhesion, 
coagulation and fibrinolysis. 
4.adherence of leucocytes to the endothelial cell surface.  
Endothelial dysfunction  vasospasm, thrombosis and inflammation 
implicated in the early stages of atherosclerotic disease. 
 Impairment of endothelial-dependent vasodilatation  is  a common finding 
observed in  healthy subjects with insulin resistance, healthy first-degree 
relatives of patients with Type 2 diabetes , and in Type 2 diabetes. Weight loss 
and physical exercise  increases insulin sensitivity associated with 
improvements in endothelial function .  
Endothelial dysfunction is also caused by:  
1.Low HDL. 
2.Hypertension 
3.Dysglycaemia 
4.Hyperuricaemia 
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5.Elevated levels of small dense LDL particles, and elevated free fatty acid 
levels. 
 6.Inflammatory cytokines including tumour necrosis factor-a (TNF-a) and IL-6 
7.Acute phase protein CRP  
8.Adipocytokines. 
The haemostatic mechanism: (12,15) 
The haemostatic system contains 2 phases: 
1.fluid phase (coagulation and fibrinolysis),  
2.a cellular phase (predominantly platelets and endothelial cells with 
contributions from macrophage ⁄ monocytes and other cells)  
3.System of receptors and binding proteins that localize thrombus formation .  
The coagulation system  complex cascade of coagulation proteins 
activation lead to thrombin generation. Thrombin generation of a cross-
linked fibrin clot, and the activation of platelets. Plasmin is the pivotal enzyme 
within the fibrinolytic cascade; its generation is regulated by plasminogen 
activators (tissue plasminogen activator, urinary-type plasminogen activator) 
that are in turn regulated by the fast acting inhibitor plasminogen activator 
inhibitor-1 (PAI-1) . Critical to an understanding of these processes is the 
recognition that they are highly regulated, integrated pathways which serve to 
maintain vascular patency whilst providing protection against blood loss by 
ensuring the appropriate balance between thrombosis and fibrinolysis within 
the circulation. 
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The haemostatic mechanism, insulin resistance and Type 2 
diabetes:(11,12) 
Many studies have established that insulin resistance is associated with a 
prothrombotic risk cluster .  Juhan-Vague et al have  demonstrated that Type 2 
diabetes is associated with profound suppression of fibrinolysis, due to elevated 
levels of the fibrinolytic inhibitor, PAI-1. Fat-laden insulin-resistant adipocyte 
generates PAI-1, strengthening the link between diabetes and suppression of 
fibrinolysis . Significant associations exist between insulin resistance and a 
variety of coagulation factors including factor VII and fibrinogen.  Clustering 
of elevated levels of PAI-1, fibrinogen , FVII and  atheromatous risk factors in 
the nondiabetic, insulin-resistant first-degree relatives of Type 2 diabetic 
subjects demonstrates the familial nature of the association between insulin 
resistance and thrombosis.  
Common soil hypothesis  states that diabetes and CVD are the same conditions 
characterized by common genetic and environmental influences. 
Fibrinolysis, insulin resistance and Type 2 diabetes: (12,15,17,19) 
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Plasminogen activator inhibitor: 
Single chain glycoprotein serine protease inhibitor (serpin)  synthesized by 
hepatocytes, fibroblasts, adipocytes, endothelial and mononuclear cells, stored 
in the  granules of platelets .  In the circulation PAI-1 forms a  complex with 
the glycoprotein vitronectin stabilizes the active conformation and increases 
its biological half-life . 
PAI-1  regulation of fibrinolysis by inhibiting the principal activator of 
plasminogen – tissue plasminogen activator (tPA) to prevent systemic plasmin 
generation and fibrin(ogen)olysis. Plasminogen activator inhibitor-1 levels are 
elevated in patients with CAD . It is  a risk factor for coronary events in 
subjects with angina  and for re-infarction post-MI . PAI-1 is  most consistently 
associated with insulin resistance. It is generally accepted as being an important 
part of the risk cluster. PAI-1 levelsstrongly correlated with components of 
the insulin resistance syndrome such as, plasma triglycerides, Body Mass Index 
, blood pressure  and insulin  in healthy subjects with insulin resistance, Type 2 
diabetic patients, and patients with known CHD.  
 
PAI-1 is also an independent risk factor for the development of Type 2 diabetes 
in healthy subjects in the Insulin Resistance Atherosclerosis Study (IRAS) , 
suggesting that they may be a very early risk marker for the development of the 
metabolic syndrome and Type 2 diabetes.  
PAI-1 levels fell Following improved insulin sensitivity (weight loss, exercise, 
metformin therapy) there was a fall in PAI-1 levels. Festa et al. study showed 
41 
 
that a fall in PAI-1 is associated with a reduction in conversion to Type 2 
diabetes .There is substantial  evidence that abnormalities in fibrinolysis occur 
very early in the course of these disorders. To test the hypothesis that 
reductions in PAI-1 would have an independent effect on conversion to 
diabetes would currently be very difficult to test as therapies which both lower 
PAI-1 and conversion to diabetes (metformin, troglitazone) also have multiple 
effects on other metabolic pathways. Increased PAI-1 secretion in vivo is 
dependent on the interaction of a number of metabolic  inflammatory factors 
which in combination, may stimulate PAI-1 secretion, but not individually , a 
hypothesis supported by both in vitro and in vivo studies.  
TISSUE PLASMINOGEN ACTIVATOR: (12,19) 
Elevated tPA  long-standing vascular damage common to insulin resistance. 
Coagulation,  and Type 2 diabetes In the Northwick Park Heart Study (NPHS) 
factor VII coagulant activity (FVII:c) levels were associated with fatal  CHD. 
Elevated levels of plasma VLDL may affect FVII:c levels either indirectly, by 
influencing kallikrein generation , or directly by providing a negatively charged 
contact surface which activates the intrinsic coagulation pathway. 
von Willebrand factor and factor VIII (12-19) 
Elevated levels of vWF⁄ FVIII to insulin resistance and Type 2 diabetes  is due 
to the presence of underlying endothelial dysfunction  and ⁄ or inflammation. 
These two factors are involved in the development of insulin resistance. 
FIBRINOGEN: (12,17) 
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Plasma levels  of fibrinogen affects  the the rheology of blood flow, blood 
viscosity and platelet aggregation there by influencing thrombogenesis. 
Epidemiological studies point out a   significant association between fibrinogen 
levels, BMI , reduced HDL and  insulin levels  (in glucose-tolerant women 
only), Majority of studies have reported plasma fibrinogen levels to be 
increased in Type 2 diabetes, in the absence  and presence of microvascular 
disease.  
FACTOR XII (12.15) 
1.Baseline levels of activated factor XII (XIIa)  is associated with 
cardiovascular risk factors like BMI, triglyceride, hypertension and FVIIc. 
2.Factor XIIa levels were strongly associated with the extent of coronary 
stenosis, and a previous history of MI.  
3.They also correlated with features of the metabolic syndrome including 
triglyceride, BMI, PAI-1, FVII:c and insulin levels . Triglycerides were an 
independent predictor of factor XIIa accounting for 21.4% of the variance in 
levels. 
Platelets, insulin resistance and Type 2 diabetes: (11,15) 
 Insulin regulates platelet function  by  acting via cell surface receptors  which 
antagonizes the platelet activating ⁄ aggregating effects of a number of agonists, 
including ADP, PAF and collagen .platelets in insulin-resistant subjects are 
resistant to the actions of insulin, NO and PGI2 , suggesting that platelet 
aggregation is upregulated in the setting of insulin resistance.  There is more 
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ready adherence and aggregation of platelets in Type 2 diabetic individuals  to 
the vascular endothelium  than in healthy subjects. 
 The other derangements include 
1. Increase in the intra-platelet calcium concentrations in insulin-resistant 
subjects, promoting platelet aggregation and activation. 
2. Enhanced atherothrombotic risk associated with the metabolic 
syndrome. Hyperglycaemia, glycation and thrombotic risk. conditions of 
eu insulinaemic hyperglycaemia,  
3. Increased levels of vWF, a glycoprotein synthesized by endothelial cells 
in subjects with type 2 diabetes, are associated with vascular injury. 
4. The plasma levels of many clotting factors including fibrinogen, factors 
VII, IX, XII, kallikrein and vWF are elevated in diabetes . This 
hypercoagulable state could be caused by an imbalance between 
hemostatic factors in plasma, and the endothelial cell surface. 
Hypofibrinolysis may occur due to reduced expression of tissue 
plasminogen activator (t-PA) , which is the most important activator of 
plasminogen, or increased plasminogen activator inhibitorPAI-1 is 
considered an independent factor of cardiovascular risk in type 2 
diabetes mellitus. 
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OBSERVATION AND RESULTS 
 
The study populations consists of 200 patients who had fulfilled 
inclusion and exclusion criteria 
Age and sex of study population was depicted below.  
Most of the cases were  > 40 years with male predominant 
Table. 6.1: Distribution of participants based on their Gender 
 
 
 
 
Chart.1.1: Distribution of participants based on their Gender 
 
58%
42%
Gender distribution
1 2
Gender Number Percentage 
Male 116 58.0 
Female 84 42.0 
Total 200 100 
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Table .6.2: Distribution of participants based on their BMI 
 
 
 
 
 
 
This study shows  67% of the patients were over weight followed by  21.5% of 
the patients were obese 
Chart:1.2 Distribution of participants based on their BMI 
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BMI category Number Percentage 
Normal 23 11.50 
Over weight 134 67.0 
Obese 43 21.5 
Total 200 100 
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Table.6.3:Distribution of participants based on their smoking history 
 
 
 
 
 
Study shows 47% of the patients had positive history of smoking 
Chart.1.3:Distribution of participants based on their smoking history 
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53%
Smoking
Yes
No
Parameter Number Percentage 
Smoking   
Yes 94 47.0 
No 106 53.0 
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Table.6.4: Distribution of participants based on their alcohol history 
 
 
 
 
 
Study shows 43.5% of the patients had positive history of alcohol 
Chart.1.4: Distribution of participants based on their alcohol history 
 
 
 
 
43%
57%
Alcohol
Yes
No
Parameter Number Percentage 
Alcohol   
Yes 87 43.5 
No 113 56.5 
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Table.6.5 :Distribution of the patient based on their blood pressure. 
Parameter Number Percentage 
Hypertension   
Yes 99 49.5 
No 101 50.5 
 
Study shows 49% of the patients had positive history of hypertension 
Chart.1.5 :Distribution of the patient based on their blood pressure. 
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Table .6.6: Distribution of participants based on their duration of Diabetes 
melitus 
 
 
 
 
 
 
Study shows 79 % of the patients had duration of diabetes < 5 years 
Chart.1.6: Distribution of participants based on their duration of Diabetes 
melitus 
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Duration of DM Number Percentage 
1-5 Years 158 79.0 
>5 Years 42 21.0 
Total 200 100 
52 
 
Table.6.7:Distribution of the participants based on their HBA1C 
 
 
 
 
 
Study shows 45.5% of the patients  were having hba1c > 9. Remaining 54.5% 
of the patients were having hba1c between 8 to 9 
Chart.1.7:Distribution of the participants based on their HBA1C 
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HbA1C Category   
8-9 109 54.5 
>9 91 45.5 
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Table.6.8: Distribution of participants based on their Fasting blood sugar 
 
 
 
 
 
shows  94% of the patients had fasting blood sugar > 125 
Chart.1.8: Distribution of participants based on their Fasting blood sugar 
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0-125 12 6.0 
>125 188 94.0 
Total 200 100 
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Table.6. 9: Distribution of participants based on their Post prandial blood sugar 
 
 
 
 
 
Study shows 87.5% of the patients had postprandial blood sugar > 200 
Chart.1. 9: Distribution of participants based on their Post prandial blood 
sugar 
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140-200 25 12.50 
>200 175 87.50 
Total 200 100 
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Table.6.10: Distribution of participants based on their total Cholesterol 
values 
 
Study shows 50% of the patient had high cholesterol level 
Chart.1.10: Distribution of participants based on their total Cholesterol 
values 
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Cholesterol category Number Percentage 
Normal 63 31.50 
Borderline high 37 18.50 
High 100 50.0 
Total 200 100 
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Table.6.11: Distribution of participants based on their LDL values 
 
Study shows 26.5% of the patient had very high LDL level followed by 24% of 
the patient had high LDL level 
Chart.1.11: Distribution of participants based on their LDL values 
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LDLcategory Number Percentage 
Normal 29 14.50 
Acceptable 40 20.0 
Borderline high 30 15.0 
High 48 24.0 
Very high 53 26.50 
Total 200 100 
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Table.6.12: Distribution of participants based on their TGL values 
 
Study shows 53.5 % of the patients had high TGL level 
Chart.1.12: Distribution of participants based on their TGL values 
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Table.6.13: Distribution of participants based on their PT and APTT 
Parameter Number Percentage 
PT,APTT   
Normal 39 19.5 
low 61 80.5 
 
Study shows 80% of the patients had low PT and APTT  values 
Chart.1.13: Distribution of participants based on their PT and APTT 
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Table.6.14: Distribution of participants based on their platelets 
 
Study shows 39.5% of the patients were having platelets >2.5 lakhs  remaining 
60.5% of the patients were having platelets between 1.5 to 2.5 lakhs 
Chart.1.14: Distribution of participants based on their platelets 
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1.5-2.5 lakhs 121 60.5 
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Table .6.15: Descriptive statistics of parameters 
 
 
 
 
 
 
 
 
Parameter Mean SD Minimum Maximum 
FBS 177.8 40.1 110 315 
PPBS 257.5 54.7 156 394 
HbA1c 9.0 0.82 8.0 11.6 
PT 10.1 1.3 7.2 13.9 
APTT 22.4 5.9 17.0 37.4 
Platelet 254184 44601 190000 355000 
Cholesterol 227.9 49.3 121 301 
LDL 153.1 40.6 78 245 
TGL 218.8 76.3 119 477 
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Table.6.16:  Difference in PT values between Gender 
Study shows no significant correlation between prothrombin time and gender 
Table.6.17:  Difference in PT values between Waist hip ratio categories 
Study shows significant correlation between prothrombin time and waist hip 
ratio. 
 
 
PT Mean SD 
Mean difference with 
95%CI 
P value 
Male 10.2 1.5 
 
0.29 (-0.7  to 0.66) 
 
0.11 
 
Female 9.9 1.1 
Independent t test: P value not significant 
WHR category Mean SD 
Mean difference with 
95%CI P value 
Normal 11.5 1.3  
1.8 (1.3-2.3) 
 
<0.001 Abnormal 9.7 1.0 
Independent t test: P value significant 
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Table.6.18:Difference in PT values between BMI categories 
 
Study shows significant correlation between prothrombin time and body mass 
index. 
Table.6.19:  Difference in PT values between smokers and non- 
smokersStudy 
shows there is no significant  correlation  between prothrombin time and 
smoking 
BMI categories Mean SD P value 
Normal 11.95 0.9  
<0.001 Overweight 10.14 1.2 
Obese 9.14 0.7 
ANOVA: P value significant 
Smoking 
status 
Mean SD Mean difference with 
95%CI 
P value 
No 10.0 1.2  
   -0.2 (-0.6  to 0.16) 
 
 0.26 Yes 10.2 1.5 
Independent t test: P value not significant 
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Table.6.20:Difference in PT values between alcoholics and non alcoholics 
 
Study shows there is no significance correlation between alcohol and 
prothrombin time 
‘Table.6.21: Difference in PT values based on hypertension 
Study shows there is no significant correlation between hypertension and PT 
 
Alcohol status Mean SD 
Mean difference with 
95%CI 
P value 
No 10.1 1.3  
-0.05 (-0.44 to 0.33) 
 
0.8 Yes 10.2 1.5 
Independent t test: P value not significant 
Hypertension Mean SD 
Mean difference with 
95%CI 
P value 
Yes 10.2 1.5  
0.2 (0.17-0.58) 
 
0.291 No 10.0 1.2 
Independent t test: P value  not significant 
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Table.6.22:  Difference in PT values between duration of  Diabetes melitus 
 
Study shows significant correlation between prothrombin time and duration 
diabetes mellitus 
Table .6.23:  Difference in PT values between Fasting blood sugar 
categories 
Study shows  significant correlation between prothrombin time and fasting 
blood sugar 
 
Duration of 
DM 
Mean SD 
Mean difference with 
95%CI 
P value 
1-5 years 10.3 1.4  
0.78 (0.41-1.2) 
 
<0.001 >5 years 9.5 1.0 
Independent t test: P value significant 
FBS 
category 
Mean SD 
Mean difference with 
95%CI 
P value 
0-125 11.6 1.5  
1.6 (0.58-2.6) 
 
0.004 >125 10.0 1.2 
Independent t test: P value significant 
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Table.6.24:  Difference in PT values between PPBS categories 
 
Study shows  significant correlation  between prothrombin time and 
postprandial blood sugar 
Table.6.25:  Difference in PT values between HbA1C categories 
Study shows significant correlation between prothrombin time and HBA1C 
 
 
 
PPBS 
category Mean SD 
Mean difference with 
95%CI P value 
140-200 12.2 0.78 
 
2.4 (2.1-2.8) 
 
<0.001 
>200 9.8 1.1 
Independent t test: P value significant 
HbA1C 
category Mean SD 
Mean difference with 
95%CI P value 
8-9 10.8 1.4 
 
1.5 (1.2-1.8) 
 
<0.001 
>9 9.3 0.7 
Independent t test: P value significant 
66 
 
Table.6.26.Difference in PT values between cholesterol categories 
Cholesterol categories Mean SD P value 
Normal 11.6 1.2 
 
<0.001 
Borderline 9.7 0.7 
High 9.4 0.7 
ANOVA: P value significant 
 
Study shows significant correlation between prothrombin time and serum 
cholesterol level 
Table.6.27.Difference in PT values between LDL categories 
LDL categories Mean SD P value 
Normal 11.8 1.1 
 
 
 
<0.001 
Acceptable 11.0 1.4 
Borderline High 9.9 0.0 
High 9.4 0.8 
Very high 9.3 0.8 
ANOVA: P value significant 
Study shows significant  correlation between prothrombin time and serum LDL 
level 
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Table.6.28. Difference in PT values between TGL categories 
TGL  categories Mean SD P value 
Normal 11.5 1.3 
 
<0.001 
Mild high 10.1 1.2 
High 9.5 0.8 
ANOVA: P value significant 
 
Study shows significant correlation between prothrombin time and TGL level 
Table6.29:  Difference in APTT values between gender 
 
Study shows significant correlation between  APTT and sex 
  
Gender Mean SD Mean difference with 95%CI P value 
Male 23.6 6.6  
2.8 (1.2-4.3) 
 
<0.001 Female 20.8 4.5 
Independent t test: P value significant 
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Table.6.30:Difference in APTT values between BMI categories 
 
 
 
 
 
 
Study shows significant correlation between APTT and body mass index. 
Table 6.31:  Difference in APTTvalues between Waist hip ratio categories 
 
Study shows significant correlation  between  APTT and waist hip ratio  
 
 
 
BMI categories Mean SD P value 
Normal 31.6 4.4 
 
<0.001 
Overweight 21.9 5.4 
Obese 19.1 2.3 
ANOVA: P value significant 
WHR category Mean SD Mean difference with 95%CI P value 
Normal 29.8 6.9 
 
9.6 (7.4-11.7) 
 
<0.001 
Abnormal 20.3 3.3 
Independent t test: P value significant 
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Table.6.32:  Difference inAPTTvalues between smokers and non- smoker 
 
Study shows significant correlation between APTT and smoking 
Table.6.33:Difference in APTT values between alcoholics and non 
alcoholics 
Alcohol status Mean SD 
Mean difference with 
95%CI 
P value 
No 21.8 5.7  
-1.5 (-3.2to0.19) 
 
0.08 Yes 23.2 6.2 
Independent t test: P value not significant 
 
Study shows there is no significant correlation between APTT and alcohol 
 
 
Smoking 
status Mean SD 
Mean difference with 
95%CI P value 
No 21.5 5.0 
 
-1.9 (-3.5—0.2) 
 
0.02 
Yes 23.4 6.7 
Independent t test: P value significant 
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Table.6.34: Difference in aPTTvalues based on hypertension 
 
Study shows there is no significant correlation between and  APT 
 
Table.6.35:  Difference inAPTTvalues between Fasting blood sugar 
categories 
 
Study shows significant correlation between APTT and fasting blood sugar 
 
Hypertension Mean SD Mean difference with 95%CI P value 
Yes 23.0 6.3 
 
1.2  (0.43-2.86) 
 
0.146 
No 21.8 5.5 
Independent t test: P value  not significant 
FBS category Mean SD Mean difference with 95%CI P value 
0-125 27.6 7.0 
 
5.5 (0.99-10.0) 
 
0.02 
>125 22.1 5.7 
Independent t test: P value significant 
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Table.6.36:  Difference inAPTTvalues between PPBS categories 
 
Study shows significant correlation between APTT and postprandial blood 
sugar. 
Table.6.37:  Difference in APTTvalues between HbA1C categories 
 
Study shows significant correlation between APTT and  HBA1C 
Table.6.38:Difference in APTT values between cholesterol categories 
 
PPBS 
category Mean SD 
Mean difference with 
95%CI P value 
140-200 33.3 4.3 
 
12.5 (10.6-14.4) 
 
<0.001 
>200 20.8 4.2 
Independent t test: P value significant 
HbA1C 
category 
Mean SD 
Mean difference with 
95%CI 
P value 
8-9 25.1 6.8  
5.9 (4.6-7.2) 
 
<0.001 >9 19.2 1.4 
Independent t test: P value significant 
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Study shows significant correlation between APTT and serum cholesterol level.  
Table.6.39.Difference in APTT values between LDL categories 
LDL categories Mean SD P value 
Normal 30.1 6.2 
<0.001 
Acceptable 26.1 7.1 
Borderline High 19.9 2.1 
High 19.1 0.8 
Very high 19.8 3.1 
ANOVA: P value significant 
Study shows significant  correlation between APTT and LDL level 
 
Cholesterol categories Mean SD P value 
Normal 28.8 6.6 
 
<0.001 
Borderline 19.4 0.7 
High 19.5 2.3 
ANOVA: P value significant 
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Table.6.40:Difference in APTT values between TGL categories 
 
 
 
 
 
 
STUDY  shows  signigicant correlation between APTT and TGL levels 
  
TGL  categories Mean SD P value 
Normal 28.6 6.6 
 
<0.001 Mild high 21.4 5.1 
High 19.5 2.2 
ANOVA: P value significant 
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DISCUSSION 
Diabetes is one of the most common disease in the world . india is the 
capital of diabetes mellitus . it affects various metabolic parameters namely 
carbohydrates, lipids and proteins it also impairs the biological process such as 
coagulation profile. The circulatory defects in these patients are characterized 
by alteration in platelet count activity, coagulopathy, haemorragic factors  and 
changes in the endothelial metabolism .  
Here  we studied  age matched diabetes mellitus with various metabolic 
and coagulation parameters . In about 200 diabetes patients 116 were 
male(58%), 84 were females(42%) ,the coagulation profile in diabetic males 
and females were studied. The statistical difference in the p value was (0.11 ) 
not found to be significant . There is no gender difference in the coagulation 
profile in patients with diabetes .  
Of about 200 diabetes patients 94 were smokers 106 were non smokers 
.The statistical difference in the P value was (0.26)  not found to be significant.  
There is a significant correlation established between diabetic smokers  and 
APTT value . The PT value  did not vary much with smokers .   
In about 200 diabetic patients 87 were  alcoholics  and 113 were non 
alcoholics were correlated .The statistical difference in the P value was  (0.8) 
not found to be  significant.  There is no significant correlation between alcohol 
status of diabetic patients with coagulation profile. 
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Here we compared the influence of hypertension in diabetic patients 
with the coagulation profile .  Of about 200  diabetic patients 99 were 
hypertensive and 101 were non hypertensive.  There is no statistically 
significant correlation established between  hypertension status of diabetic 
patients and coagulation profile. 
             The influence of duration of diabetes on the effect of coagulation 
profile was studied .  Of about 200 diabetic patients 42 patients were having 
diabetes  for more than 5 years , remaining 158 patients were having duration 
of diabetes between 1 to 5 years. There  is significant  correlation between 
duration of diabetes and coagulation profile 
           Here we correlated BMI and WHR of diabetic patient with their 
coagulation parameters of about . 43 patients were obese 134 patients were 
over weight remaining 23 patients were having normal BMI. The statistical 
difference in the p value both BMI and WHR  was <0.001 which was 
statistically significant 
       The  HbA1c levels of diabetic patients  with coagulation profile was 
studied .Out of 200 patients 91 patients were having  hba1c  >9. 109 patients 
were having hba1c between 8 to 9. The statistical difference in the P value was 
<0.001 which was found to be significant.  
               Fasting blood glucose levels of diabetic patients with coagulation 
profile  was correlated in this study . Of about 200 diabetic patients 188 
patients were having blood sugar >125 mg/dl . 12 patients were having blood 
sugar under control.  Most of the patients with poor  glycemic control were 
76 
 
having shortened PT and APTT.  The statistical difference in the P value was 
0.004. There is statistically significant correlation between poorly glycemic 
control patients and their coagulation profile. 
In this study we correlated PPBS of diabetic patients with their 
coagulation profile.  Out of 200 patients 175 patients were having  PPBS more 
than 200mg/dl , remaining 25 patients were having  PPBS  between 140 to 200. 
Most of the patients with poorly controlled  glycemic  status were having 
shortened PT and APTT. The statistical difference in the p value was <0.001.  
There is statistical  significant in the correlation between uncontrolled PPBS 
and their coagulation profile. 
In this study we correlated lipid profile of diabetic patients were having  
Hba1c >8 with their coagulation profile .  The statistical  difference in the p 
value was <0.001.  There is statistical significant correlation between lipid 
profile of diabetic individuals and their coagulation profile. 
The influence of BMI in diabetic patients on the coagulation status was 
studied . the mean value of the overweight and obese patients were found to be 
21 and 19 respectively . there is a statistically significant value between the 
obesity and aPTT values in patients with diabetes. There is also a positive 
correlation between the value and the diabetic patients with obesity . the mean 
cholesterol levels in diabetic patients with high values were found to be 19.5. 
similarly the p value significance of cholesterol, LDL,TGL levels with 
coagulation profile (both PT and aPTT) levels .   
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SUMMARY   
                   Diabetes mellitus is a heterogeneous disease affecting metabolism 
of various compounds . the effect of diabetes mellitus on coagulation status has 
not been studied in detail thus far .  Diabetes itself is a procoagulant state .  
Thus diabetic patients are more prone for many thromboembolic events .  In 
patients with diabetes mellitus abnormalities in coagulation haemostasis, platlet 
dysfunction and reduced activity of fibrinolytic system can collectively 
accelerate atherogenesis in diabetic patients . Merlo et al reported an increase 
in the tissue factor and subsequent conversion of  inactive factor VII to its 
active form thus initiating the extrinsic pathway . Hyperglycemic is found to be 
a soul causative factor in these alteration the in the coagulation profile  . This 
predisposes the patients with diabetes for microvascular and macrovascular 
complications . Several studies have shown that the level of PT is increased in 
patients with poorly controlled glycemic levels except for those patients who 
are smokers. The real reason for the abnormal activation of clotting mechanism 
has not been clearly established. There is a proposed theory stating that 
hyperglycemia leads to inactivation of antithrombin III . Thus there are multi 
factorial causative agents leading on to hypercoagulable  status in patients with 
diabetes mellitus . 
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CONCLUSION 
                   A study on the coagulation profile in type 2 diabetes mellitus in 
correlation with long term glycemic control was conducted in Coimbatore 
medical college hospital during the year June 2016 to July 2017 . Various 
metabolic parameters  in patients with diabetes mellitus  and its influence on 
the coagulation profile has been studied.  
1) The high prevalence of altered coagulation profile in patients with 
DM has been established. 
2) The effect of hypercoagulable state on the microvascular and 
macrovascular complications in patients with diabetes mellitus 
should be considered  
3) Therefore the treatment of hypercoagulable state may have a 
preventive role in micro and macrovascular complications in patients 
with diabetes mellitus.  
4) Thus the effective control of glycemic status which leads on to the 
alteration in the coagulation profile should be emphasized. 
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S. 
NO NAME AGE SEX BMI 
 
W.H 
RATIO 
 
DM 
DURATION 
(YEARS) 
HYPERT
ENSIVE 
OR NOT 
SMOKING ALCOHOL FBS PPBS  (2HRS) 
HBA1C 
>8 PT APTT 
PLAT
ELET CHOLESTEROL LDL TGL 
1 NARAYANAN 52 M 28.2 0.92 2 YES YES YES 158 226 8.5 9.25 19.62 284000 200 114 150 
2 GANESAN 49 M 26.8 0.88 5 YES YES NO 140 206 8.2 10.12 19.40 312000 198 129 152 
3 RUKMANI 48 F 30.4 1.11 4 NO NO NO 194 243 8.9 9.64 19.01 198000 223 158 197 
4 GOVINDA RAJ 66 M 
25.9 
 
0.97 4 YES YES YES 164 223 8.5 10.54 18.32 225000 190 129 148 
5 NAGAMMAL 57 F 30.1 0.99 3 NO NO NO 215 283 9.0 9.44 19.14 234000 253 162 252 
6 CHELLAIYAN 65 M 24.9 0.84 3 YES NO YES 141 198 8.0 13.40 30.21 211000 173 130 150 
7 PARAMASIVAM 41 M 31.1 1.23 5 YES YES YES 222 311 9.2 8.20 19.43 250000 241 169 274 
8 KARUNANIDHI 77 M 26.4 0.96 2 NO YES YES 144 245 8.8 9.54 19.94 195000 211 136 162 
9 SARASWATHI 66 F 29.1 1.01 3 YES 
NO 
 
NO 250 298 10.0 9.66 18.74 288000 257 170 284 
10 SIVAGAMI 55 F 26.8 0.99 6 NO NO NO 141 207 8.1 12.33 26.98 323000 164 109 149 
11 BALAMURUGAN 44 M 25.0 0.80 4 NO YES YES 133 184 8.0 12.21 35.30 222000 192 112 151 
12 MARIMUTHU 67 M 27.4 0.98 5 NO NO NO 198 238 9.3 8.77 17.45 250000 211 159 201 
13 MUTHUSAMY 80 M 26.8 0.99 8 YES YES YES 221 301 9.5 7.23 18.90 344000 223 174 211 
14 MAGESHWARI 68 F 23.6 0.79 2 NO NO NO 124 173 8.0 13.89 32.76 234000 159 99 149 
15 MARUDHACHALLAM 49 M 25.5 0.82 2 YES YES NO 147 196 8.2 10.70 19.33 321000 209 135 154 
16 BANUMATHI 55 F 30.3 1.01 7 YES NO NO 245 301 9.3 8.54 17.09 211500 273 188 298 
17 KESAVAN 77 M 27.6 0.99 6 NO NO YES 139 203 8.1 10.42 19.32 276500 188 121 148 
18 XAVIER 63 M 26.6 0.98 4 NO YES NO 226 298 9.4 9.67 19.77 250000 239 158 222 
19 SAHAYAMARY 42 F 25.0 0.85 2 YES NO NO 199 276 9.0 9.87 19.55 195000 154 101 145 
MASTER CHART 
 
 
20 MOHAMMED FAIZAL 61 M 29.1 1.00 6 NO NO YES 254 394 9.9 8.78 19.87 234500 255 189 301 
S. 
NO NAME AGE SEX BMI 
 
W.H 
RATIO 
 
DM 
DURATION 
(YEARS) 
HYPERT
ENSIVE 
OR NOT 
SMOKING ALCOHOL FBS PPBS  (2HRS) 
HBA1C 
>8 PT APTT 
PLAT
ELET CHOLESTEROL LDL TGL 
21 MADHAVAN 52 M 28.2 0.99 2 YES YES YES 189 234 8.5 9.25 19.62 284000 225 164 199 
22 BALAJI 49 M 26.8 0.88 5 YES NO NO 142 206 8.2 9.12 19.40 312000 211 147 156 
23 FATHIMA BEEVI 48 F 30.4 1.11 4 NO NO NO 194 243 10.1 9.64 19.01 198000 273 191 327 
24 ANTHONY RAJ 66 M 24.2  0.91 4 YES YES YES 132 198 8.0 12.54 31.32 225000 154 111 145 
25 MALAR KODI 57 F 30.1 1.01 3 NO NO NO 201 298 9.8 9.44 18.14 234000 264 185 221 
26 PALANIYAPPAN 65 M 24.9 0.84 3 YES NO YES 115 198 8.0 11.98 30.21 211000 165 123 151 
27 MASANI 51 M 31.1 1.23 5 YES YES YES 255 374 11.2 8.20 19.43 250000 288 198 399 
28 BHAGATHSINGH 77 M 25.4 0.96 2 NO YES YES 154 245 8.8 9.54 19.94 195000 201 102 151 
29 MARIYAMMAL 56 F 31.1 1.01 4 YES NO  NO 200 282 9.8 10.66 19.74 288000 276 190 301 
30 MARIYAPUSHPAM 55 F 26.8 0.99 6 NO NO NO 146 212 8.1 9.33 20.98 323000 189 112 149 
31 ABUTHAGIR 44 M 25.0 0.80 4 NO YES YES 137 221 8.0 12.21 35.30 222000 176 122 154 
32 VIMALRAJ 67 M 27.4 0.98 5 NO YES NO 160 238 9.3 10.77 19.45 250000 240 161 311 
 
 
33 MOHAMMED FAROOK 60 M 30.8 0.90 8 YES YES YES 214 289 9.5 9.23 18.90 344000 288 171 252 
34 VELLAMMAL 68 F 26.6 0.93 5 NO NO NO 148 223 8.2 10.89 20.76 234000 188 128 162 
S. 
NO NAME AGE SEX BMI 
 
W.H 
RATIO 
 
DM 
DURATION 
(YEARS) 
HYPERT
ENSIVE 
OR NOT 
SMOKING ALCOHOL FBS PPBS  (2HRS) 
HBA1C 
>8 PT APTT 
PLAT
ELET CHOLESTEROL LDL TGL 
35 ANADRAJ 49 M 25.5 0.82 2 YES YES NO 116 156 8.0 12.70 37.33 321000 179 125 158 
36 KARPAGAM 55 F 30.3 1.01 7 YES NO NO 222 301 10.8 9.54 19.09 211500 241 190 266 
37 KITTAN 77 M 24.6 0.90 6 NO YES YES 110 203 8.1 10.42 19.32 276500 198 128 147 
38 SIVALINGAM 63 M 26.6 0.91 4 NO YES NO 176 298 9.4 9.67 19.77 250000 232 160 286 
39 NISHA 42 F 25.9 0.85 2 YES NO NO 144 226 8.0 9.87 19.55 195000 165 99 152 
40 RAJAN 61 M 29.1 1.00 6 NO NO YES 222 394 9.9 8.78 19.87 234500 255 187 221 
41 AYYAPAN 42 M 27.2 0.99 3 NO YES YES 198 226 9.1 9.11 19.56 282000 239 149 188 
42 MURGAN 59 M 27.8 0.98 3 YES YES YES 141 219 8.4 10.22 20.22 333000 224 131 187 
43 PARVATHI 58 F 29.4 1.00 5 NO NO NO 185 233 8.9 9.54 19.21 195000 265 161 232 
44 PERMUAL 56 M 25.5  0.92 4 YES YES YES 134 213 8.1 12.98 26.76 225500 156 98 134 
45 SAROJA 47 F 30.3 1.12 5 NO NO NO 144 221 8.2 9.34 17.43 234500 257 188 321 
 
 
46 SHANTHI 55 F 25.0 0.88 3 YES NO NO 125 188 8.0 12.11 32.30 211500 166 101 148 
47 JANAKI 47 M 32.0 1.13 4 NO YES YES 212 310 9.1 8.21 19.33 250500 267 191 334 
48 VELMURGAN 67 M 25.4 0.91 5 YES YES NO 143 235 8.1 13.44 30.93 190000 189 106 132 
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49 FATHIMA 56 F 29.0 1.01 3 NO NO NO 220 272 8.9 9.55 19.64 285700 288 199 377 
50 SAMIYAMMAL 65 F 27.8 0.88 5 YES NO NO 166 233 8.4 9.22 18.88 323500 221 123 151 
51 MANIKAM 54 M 25.9 0.90 6 NO YES NO 142 211 8.0 12.11 35.43 222500 187 110 148 
52 GOVINDHA SAMI 62 M 28.4 0.99 5 YES YES YES 215 268 9.2 9.66 19.44 255500 234 131 166 
53 PERIYA SAMI 78 M 27.4 0.97 6 YES NO YES 198 279 9.4 9.23 18.90 344000 245 174 221 
54 PONNAMAL 58 F 27.6 0.99 5 YES NO NO 175 222 9.2 9.79 19.60 234500 211 131 151 
55 SATTAMUTHU 69 F 25.9 0.91 4 YES NO NO 136 188 8.7 12.87 37.43 325000 143 98 144 
56 VJIRAVATHI 56 F 30.4 1.01 5 NO NO NO 243 343 10.4 9.54 17.09 211500 298 190 297 
57 VISHAWANATHAN 67 M 27.6 0.99 6 YES YES YES 151 213 8.3 10.42 19.22 270000 243 134 156 
58 VISHNU RAM 53 M 26.6 0.88 5 NO YES YES 176 288 9.4 9.57 19.67 256900 266 187 254 
 
 
59 PREMA 62 F 26.7 0.99 3 YES NO NO 144 276 9.0 1O.87 18.55 195000 221 129 199 
60 JOTHIMANI 51 F 29.8 1.00 5 NO YES NO 201 374 9.6 9.65 19.37 234500 255 196 223 
61 KANDHASAMY 58 M 29.2 0.99 5 YES NO YES 148 222 8.5 9.25 19.62 284000 211 129 151 
62 KALIDOSS 49 M 26.8 0.98 5 YES YES NO 192 226 8.2 9.12 19.40 312000 201 122 152 
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63 SUBALAKSHMI 48 F 30.4 1.11 4 NO NO NO 201 243 9.8 9.64 17.01 198000 266 199 222 
64 SASI 66 M 25.9  0.97 4 YES YES YES 174 273 8.5 10.54 20.32 225000 238 142 200 
65 MANGAIAMMAL 57 F 30.1 0.98 3 NO NO NO 198 273 9.0 9.44 29.14 234000 267 201 232 
66 FRANCIS 65 M 24.9 0.84 3 YES NO YES 135 198 8.0 12.05 30.21 211000 173 98 132 
67 IBRAHIM 41 M 31.1 1.23 5 YES YES YES 274 389 11.6 8.20 17.43 250000 288 243 398 
68 LOUIS 77 M 26.4 0.96 2 NO YES YES 147 245 8.8 9.54 19.94 195000 198 101 148 
69 POVUNAMMAL 66 F 29.1 1.01 5 YES NO  NO 245 299 10.4 8.66 19.74 288000 279 245 311 
70 SHANTHI 55 F 26.8 0.99 6 NO NO NO 166 232 8.1 9.33 20.98 323000 187 100 132 
71 KARUPPAIYAN 44 M 25.0 0.80 4 NO YES YES 142 198 8.0 12.21 35.30 222000 145 101 134 
 
 
72 ARIVAZHAN 67 M 27.4 0.98 5 NO NO NO 211 298 9.3 9.77 
18.45 
 
 
250000 255 166 233 
73 MANIYAPPAN 80 M 26.8 0.90 8 YES YES YES 193 289 9.5 9.23 19.90 344000 237 144 202 
74 MUTHAMMAL 68 F 25.6 0.82 5 NO NO NO 124 213 8.2 13.89 29.76 234000 173 121 148 
75 PAUL RAJ 49 M 25.5 0.82 2 YES YES NO 136 178 8.0 12.70 37.33 321000 167 123 145 
76 AROKIYA MERY 55 F 30.3 1.01 7 YES NO NO 2266 301 10.3 9.54 18.09 211500 288 201 224 
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77 THANRAJ 77 M 27.6 0.99 6 NO YES YES 221 305 9.8 9.42 19.32 276500 245 198 242 
78 DAVID 63 M 26.6 0.91 4 NO YES NO 211 298 9.4 9.67 19.77 250000 235 191 298 
79 RUBI 42 F 25.1 0.79 2 YES NO NO 144 201 8.0 12.87 30.55 195000 145 99 134 
80 THANDABANI 61 M 29.1 1.00 6 NO NO YES 222 394 9.9 8.78 19.87 234500 249 195 277 
81 ARUMUGAM 53 M 28.4 1.01 3 NO YES YES 244 345 10.5 9.26 17.26 247800 257 169 221 
82 CHANDRA BOSE 50 M 27.8 0.99 4 YES YES YES 201 264 9.7 9.32 18.39 316700 226 149 199 
83 JEEVITHA 49 F 30.3 1.10 5 NO NO NO 193 247 9.6 9.66 19.11 195600 262 178 197 
84 SUNDRAM 65 M 25.0  0.93 4 YES YES YES 135 212 8.1 12.65 31.33 228900 191 101 142 
 
 
85 SELVI 55 F 29.9 0.97 2 NO NO NO 176 274 9.2 9.46 19.21 265400 241 192 201 
86 RAJU 64 M 24.8 0.88 4 NO YES YES 127 179 8.2 12.24 30.41 214700 169 92 121 
87 LATHA 42 F 31.1 1.23 5 YES NO NO 2O1 310 9.1 8.22 19.47 254000 277 189 196 
88 RAVI 70 M 26.5 0.99 3 NO YES NO 177 259 8.9 9.55 19.93 194000 250 191 199 
89 SUGUNA 64 F 29.2 1.02 2 YES NO  NO 231 333 10.3 8.67 17.75 288500 267 179 222 
90 MERRYAMMA 53 F 26.7 0.98 5 NO NO NO 145 233 8.2 9.34 19.77 323500 170 97 120 
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91 ARUL 43 M 25.1 0.82 3 YES NO YES 143 202 8.1 12.20 35.31 222600 168 100 119 
92 AYSHA BEGUM 66 F 27.3 0.97 4 YES NO NO 194 237 9.4 9.76 19.44 255000 221 154 201 
93 VEERAIYAN 81 M 26.7 0.91 7 NO YES YES 184 248 9.3 9.24 18.91 344500 223 157 212 
94 SUMATHI 67 F 26.4 0.92 4 YES NO NO 125 224 8.7 10.88 20.77 234500 211 136 169 
95 IMRAN KHAN 48 M 25.3 0.83 3 YES YES YES 137 194 8.2 12.71 37.34 321500 188 101 143 
96 LALITHA 54 F 30.2 1.02 5 NO NO NO 214 298 10.2 8.44 18.08 211400 288 197 312 
97 KULDEEP 74 M 27.5 0.98 3 YES YES YES 142 204 8.3 10.12 19.12 276400 134 105 144 
 
 
98 MOHIT SHARMA 62 M 26.7 0.92 4 YES YES YES 194 297 9.3 9.68 19.73 255400 250 188 287 
99 NARMADHA 43 F 25.8 0.84 3 YES NO YES 195 274 9.2 1O.37 19.45 195500 222 155 213 
100 NALLAKUMAR 60 M 30.2 1.00 5 NO YES NO 221 393 9.9 8.77 19.86 234300 299 198 355 
101 ARUMUGAM 72 M 26.4 0.99 4 NO YES NO 158 276 8.6 9.88 19.42 287600 223 143 201 
102 PAKKIRISAMY 58 M 28.4 0.99 5 YES YES YES 172 246 9.3 9.53 20.04 256400 227 154 221 
103 NISATH BEGUM 59 F 30.4 1.11 4 NO NO NO 244 343 10.4 9.64 17.01 225000 287 198 274 
104 MARATHAL 61 F 25.9  0.80 4 YES NO NO 134 193 8.2 12.64 34.13 328900 185 92 139 
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1O5 MUMTAJ 48 F 30.1 1.23 3 NO NO NO 215 311 9.9 9.44 19.14 234000 277 192 256 
106 SHANMUGAM 55 M 24.1 0.84 3 YES N0 YES 125 198 8.0 12.01 30.20 211000 166 91 127 
107 SHAKULAMMED 41 M 31.1 1.23 5 YES YES YES 282 371 11.2 8.20 19.43 250000 299 199 289 
108 ARUNACHALAM 77 M 26.4 0.96 2 NO YES YES 164 245 8.8 9.32 19.54 245000 224 145 203 
109 PADMAVATHY 62 F 29.1 1.01 3 YES NO  NO 200 272 9.4 10.66 19.74 254000 276 193 238 
110 KARPAGAM 45 F 26.8 0.99 6 NO NO NO 146 232 8.3 9.33 20.98 325000 228 155 219 
 
 
111 MARIMUTHU 54 M 25.0 0.80 4 NO YES YES 162 221 8.1 12.21 35.30 222000 186 98 137 
112 XAVIER 57 M 27.4 0.98 5 YES YES YES 160 248 9.3 9.77 19.46 265300 245 191 221 
113 NARAYANAN 70 F 26.8 0.90 6 YES NO NO 133 229 8.5 9.23 19.03 355000 221 132 164 
114 VICTORIA 58 F 26.6 0.93 5 NO NO NO 141 233 8.2 10.89 19.76 254000 220 133 163 
115 PERIYANNAN 49 M 25.5 0.82 2 NO YES YES 126 156 8.1 12.70 37.33 321000 134 100 146 
116 AMBIKAVATHY 55 F 30.3 1.01 7 YES NO NO 246 321 9.9 1O.54 17.56 211500 287 187 254 
117 MURUGAIYAN 72 M 27.6 0.99 5 NO YES YES 150 203 8.3 10.42 19.32 276500 221 134 165 
118 FAROOK 63 M 26.6 0.91 4 YES YES YES 196 298 9.4 9.67 19.77 250000 266 199 223 
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119 AMMANIYAMMAL 42 F 25.9 0.95 2 NO NO NO 164 276 9.0 1O.87 19.55 195000 233 181 210 
120 SELVI 60 F 29.6 1.00 4 YES NO NO 222 323 9.9 8.78 19.87 234500 286 187 253 
121 MAYILSAMY 53 M 28.3 0.93 3 YES YES YES 159 207 8.5 9.26 19.61 285000 248 178 165 
122 SAROJA 50 F 26.8 0.88 5 NO NO NO 191 224 8.4 9.12 19.23 312000 247 187 171 
123 POOMATHY 61 F 30.4 1.11 4 NO NO NO 214 293 9.9 9.64 19.01 198000 287 191 288 
 
 
124 RAMADOSS 66 M 25.9  0.97 4 YES YES YES 144 223 8.2 12.54 27.32 225000 177 98 137 
125 INDURANI 57 F 30.1 1.52 3 NO NO NO 214 291 9.8 9.44 19.14 234000 289 193 288 
126 BALAIYAN 65 M 24.9 0.84 3 YES N0 YES 135 198 8.0 11.01 30.23 211000 188 99 147 
127 SANNASI 41 M 31.1 1.23 5 YES YES YES 242 311 9.8 8.20 19.43 250000 288 194 266 
128 SOMASUNDARAM 77 M 26.4 0.96 2 NO YES YES 164 245 8.8 9.54 19.94 195000 247 179 166 
129 NOORJAHAN 66 F 29.1 1.01 4 YES NO  NO 201 282 9.4 8.66 18.74 288000 267 173 194 
130 MARATHAL 55 F 26.8 0.99 6 NO NO NO 176 232 8.9 9.33 17.98 323000 201 101 141 
131 MURUGESAN 44 M 25.0 0.80 4 N0 YES YES 142 211 8.1 12.21 35.30 222000 286 190 265 
132 MUTHUSAMY 67 M 27.4 0.98 5 NO YES NO 160 238 9.3 10.77 19.45 250000 255 169 301 
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133 SIVARAJ 80 M 26.8 0.90 8 YES YES YES 193 289 9.5 9.23 18.90 344000 279 182 321 
134 RUKMANI 68 F 26.6 0.93 5 NO NO NO 154 223 8.8 9.89 19.76 234000 248 158 278 
135 GOPAL 49 M 25.1 0.82 2 YES YES NO 136 186 8.0 12.70 37.33 321000 155 89 132 
136 LAKSHMI 55 F 30.3 1.01 7 YES NO NO 196 301 9.8 8.54 17.09 211500 298 199 331 
 
 
137 GURUSAMY 46 M 27.6 0.99 6 NO YES YES 140 203 8.1 9.42 19.32 276500 278 181 265 
138 ABUTHAKIR 63 M 26.6 0.91 4 NO YES NO 176 298 9.4 9.67 19.77 250000 249 157 268 
139 SELVARANI 42 F 25.1 0.85 2 YES NO NO 144 276 8.0 1O.87 19.55 195000 166 94 143 
140 UMA 54 F 29.1 1.00 6 NO NO NO 222 394 9.9 8.78 19.87 234500 280 183 288 
141 NAGARAJAN 52 M 25.2 0.92 2 NO YES YES 138 206 8.0 11.25 29.62 284000 165 105 138 
142 VIJAYAKUMAR 49 M 25.8 0.88 5 YES YES NO 142 217 8.1 10.12 26.40 312000 172 111 142 
143 GEETHA 48 F 30.4 1.11 4 NO NO NO 194 243 8.9 9.64 19.01 198000 255 163 258 
144 MOHAMMEDNIVAS 66 M 25.9  0.97 4 YES YES YES 174 273 8.5 10.54 19.32 225000 246 175 278 
145 SEETHALAKSHMI 57 F 30.1 1.92 3 NO NO NO 217 311 9.9 9.44 17.14 234000 288 191 286 
146 LINGON 65 M 24.9 0.84 3 YES NO YES 135 198 8.0 11.05 30.27 211000 132 99 132 
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147 THIRUNAVUKARASU 41 M 31.1 1.23 5 NO YES NO 2O2 334 9.2 8.20 19.43 250000 272 178 227 
148 AVUDAIYAPPAN 77 M 26.4 0.96 2 NO YES YES 124 245 8.2 9.54 19.94 195000 154 98 127 
149 RAHAMATHNISHA 66 F 29.1 1.01 1 YES NO  NO 210 292 9.4 10.66 23.74 288000 299 198 351 
 
 
150 KUMUTHAVALLI 55 F 26.8 0.99 6 NO NO NO 146 232 8.1 9.33 20.98 323000 199 100 138 
151 LENIN 44 M 25.0 0.80 4 N0 NO YES 132 201 8.1 12.21 35.30 222000 154 92 132 
152 CHELLAPPAN 67 M 27.4 0.98 5 NO YES NO 160 238 9.3 10.77 18.45 250000 234 189 255 
153 RAMAN 80 M 26.8 0.90 8 YES NO YES 213 3159 9.8 9.23 19.90 344000 266 193 367 
154 LAKSHMI 68 F 26.6 0.93 5 NO NO NO 124 213 8.2 9.89 20.76 234000 139 88 122 
155 NARASIMMAN 49 M 25.5 0.82 2 YES YES NO 126 196 8.0 12.70 37.33 321000 168 94 133 
156 NIRMALA MARY 55 F 30.3 1.01 7 YES NO NO 206 301 9.7 8.54 28.09 211500 276 192 311 
157 AVUDAIYAPPAN 77 M 27.6 0.99 6 NO YES YES 140 203 8.1 11.42 29.32 276500 149 91 121 
158 SIVAKUMAR 63 M 26.6 0.91 4 NO NO NO 196 298 9.4 9.67 19.77 250000 298 199 389 
159 MANOHARI 42 F 25.9 0.85 2 YES NO NO 184 276 9.0 9.87 19.55 195000 288 189 378 
160 NATARAJAN 61 M 29.1 1.00 6 NO NO YES 222 394 9.9 8.78 19.87 234500 301 221 398 
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161 MURUGAN 58 M 29.2 0.99 5 YES YES YES 158 206 8.5 9.25 19.62 284000 240 189 199 
162 RAJAN 49 M 26.8 0.88 5 YES YES NO 142 226 8.2 10.12 26.40 312000 143 101 134 
 
 
163 BOMMIYAMMAL 48 F 30.4 1.11 4 NO NO NO 194 243 9.9 9.64 17.01 198000 271 198 289 
164 ANANDRAJ 66 M 25.9  0.97 4 YES YES YES 144 233 8.2 11.54 27.32 225000 158 99 144 
165 KULSATHBEGUM 57 F 30.1 1.22 3 NO NO NO 194 281 10..0 9.44 19.14 234000 289 197 288 
166 NEDUMARAN 65 M 24.9 0.84 3 YES NO YES 315 198 8.0 11.03 30.22 211000 167 100 148 
167 VEERASAMY 41 M 31.1 1.23 5 YES YES YES 222 311 9.9 8.20 19.43 250000 278 195 288  
168 KARUPPUSAMY 77 M 26.4 0.96 2 NO YES YES 174 245 8.8 9.54 19.94 195000 241 190 222 
169 VARALAKSMI 66 F 29.1 1.01 5 YES NO  NO 210 282 9.8 9.66 17.74 288000 277 196 302 
170 INBAVALLI 55 F 26.8 0.99 6 NO NO NO 146 232 8.1 11.33 29.98 323000 155 97 140 
171 BALAN 44 M 25.0 0.80 4 NO YES YES 152 221 8.1 12.21 35.30 222000 121 78 124 
172 MANIYAN 67 M 27.4 0.98 5 NO NO NO 160 238 9.3 9.77 19.45 250000 266 189 299 
173 KITTAN 80 M 26.8 0.90 8 YES YES YES 193 289 9.5 9.23 19.90 344000 287 199 302 
174 MARY 68 F 26.6 0.93 5 NO NO NO 144 223 8.2 10.89 20.76 234000 133 101 144 
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175 VINCENT 49 M 25.5 0.82 2 YES YES NO 116 156 8.0 12.70 37.33 321000 129 79 126 
 
 
176 SOFIA 55 F 30.3 1.01 7 YES NO NO 218 301 10.3 9.54 18.09 211500 265 188 298 
177 MUNIYAMMAL 77 M 27.6 0.99 6 NO YES YES 160 203 8.9 10.42 19.32 276500 244 157 267 
178 GANESAN 63 M 26.6 0.91 4 NO YES NO 176 298 9.4 9.67 19.77 250000 299 199 329 
179 GOMATHI 42 F 25.9 0.85 2 YES NO NO 154 276 9.0 9.87 19.55 195000 245 158 266 
180 SAMINATHAN 61 M 29.1 1.00 6 NO NO YES 222 394 10.9 8.78 19.87 234500 301 202 477 
181 AMARAVATHY 55 F 30.1 1.11 6 YES NO NO 244 322 10.3 9.24 19.43 274000 298 199 388 
182 NAGAPPAN 59 M 26.8 0.99 5 YES YES YES 182 246 9.2 10.22 19.13 315000 265 178 299 
183 SUBBAMMAL 68 F 30.6 1.12 5 NO NO NO 234 303 9.9 9.64 18.06 245000 297 198 323 
184 NIVAS 46 M 31.0  1.27 4 YES YES YES 275 394 10.6 8.54 17.86 215000 299 198 378 
185 NISATH BEGUM 55 F 30.1 1.00 3 NO NO NO 194 271 9.8 9.44 19.94 234000 287 188 298 
186 SARASWATHI 65 F 24.9 0.84 3 YES N0 N0 135 198 8.0 11.01 35.22 211000 162 99 132 
187 AROKIYAMARY 41 M 31.1 1.23 5 YES YES YES 212 311 9.2 8.20 19.43 250000 279 187 277 
188 MOORTHY 77 M 26.4 0.96 2 NO YES YES 124 245 8.2 9.54 19.94 195000 177 100 142 
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189 THANNASI 57 F 29.1 1.01 5 YES NO  N0 190 282 8.9 9.66 19.74 288000 267 177 266 
190 KANNAGI 55 F 26.8 0.99 6 NO NO N0 176 232 8.8 9.33 20.98 323000 245 188 267 
191 SADAGOPAN 44 M 25.0 0.80 4 N0 YES YES 162 211 8.2 12.21 35.30 222000 143 88 133 
192 MEENAKSHI 68 F 27.4 0.98 5 YES NO NO 160 238 9.3 9.77 19.24 250000 246 190 288 
193 MURUGESAN 80 M 26.8 0.90 8 YES YES YES 163 289 9.5 9.23 19.90 344000 256 193 278 
194 NEELAVENI 68 F 26.6 0.93 5 NO NO NO 154 225 8.6 10.89 19.76 234500 244 187 266 
195 BALAMURUGAN 50 M 25.6 0.85 4 YES YES NO 134 163 8.1 12.70 37.33 321000 133 92 141 
196 AMARAVATHY 54 F 30.3 1.01 5 YES NO NO 276 301 9.9 1O.54 19.09 217900 266 198 277 
197 KASINATHAN 70 M 27.6 0.99 6 NO YES YES 155 224 8.6 10.42 19.32 276500 244 189 261 
198 KOMALAVALLI 62 F 26.6 0.91 4 NO NO NO 196 298 9.4 9.67 19.77 250000 276 195 301 
199 KULSATH BEGUM 42 F 25.9 0.85 2 YES NO NO 148 224 8.2 1O.87 19.75 222000 143 98 145 
200 SABOOL 59 M 29.1 1.00 6 NO YES YES 222 394 10.9 8.78 19.87 234500 298 200 308 
 
 
PROFORMA 
AGE: 
SEX: 
ADDRESS: 
CHIEF COMPLAINTS: 
PERSONAL HISTORY; SMOKING ,ALCOHOLISM 
FAMILY HISTORY 
PAST HISTORY; HYPERTENSION ,CORONARY ARTERY DISEASE, 
CEREBRO VASCULAR ACCIDENT,LIVER 
DISEASE,MALIGNANCY,COAGULATION DISORDERS, KIDNEY 
DISEASE,ANY DRUGS ALTERING  COAGULATION PROFILE 
TREATMENT HISTORY: 
GENERAL EXAMINATION: 
VITALS ,BMI AND WHRS 
YSTEM EXAMINATION: 
INVESTIGATIONS:COMPLETE BLOOD COUNT , PT, APTT,LIVER 
FUNCTION TEST,FBS, PPBS,HBAIC, LIPID PROFILE, RENAL 
FUNCTION TEST, URINE ROUTINE, CT BRAIN, ULTRA SOUND 
ABDOMEN. 
DIAGNOSIS: 
 
 
 
 
